BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260515T172757
CREATED:20240423T145330Z
LAST-MODIFIED:20240423T145330Z
UID:39018-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:2nd RNA Assay Development Screening Summit
DESCRIPTION:There has been many exciting investments and advancements in the field\, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 expanding their partnership to accelerate development of neuroscience drugs. However\, the discovery of potent RNA targeting small molecules is plagued by limited robust assays and screening methods for understanding the RNA target structure as well as the mechanism of action of the small molecule drugs. \nHence\, this August the 2nd RNA Assay Development & Screening Summit returns to Boston as the first and only industry dedicated event on developing sensitive\, and reproducible assay and screening methods. With 70% brand new speaker faculty from key stakeholder companies as well as new companies entering the field\, including the likes of AstraZeneca\, Arrakis Therapeutics\, Molecure\, Wayfinder Biosciences\, Biogen and more\, access the latest strategies for developing reproducible and sensitive assay and screening methods. \nDownload the free brochure or book your place now\, early birds are still available!
URL:http://www.pharmajournalist.com/event/2nd-rna-assay-development-screening-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260515T172757
CREATED:20240515T095414Z
LAST-MODIFIED:20240515T095414Z
UID:39112-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:5th Gene Therapy Immunogenicity Summit
DESCRIPTION:Optimize Safety & De-Risk Efficacy of Viral Vector-Based Gene Therapies \nThe success of gene therapy hinges on overcoming the immunogenicity challenges of viral vectors. With more viral vector-based gene therapies progressing through the pipeline\, we need to seek solutions to this critical bottleneck ‘here and now’. \nThe 5th Gene Therapy Immunogenicity Summit is returning to Boston this August\, bringing together 100+ immunogenicity experts responsible for predicting\, measuring\, and mitigating immune response. Join your colleagues as they share their learnings and gain key insights on: \n \n\nEffective approaches to promote AAV safety whilst maintaining efficacy\nPreventing the bottlenecks of the potential slowdown of gene therapy development\n\nAccess specific\, case-study-led examples across immunogenicity and ask the big-hitting immunology questions to your peers actively working in the space to make clinically safe and effective gene therapies a reality. \n\nPredicting and mitigating against complement activation and other toxicity issues with Ask Bio\, Takeda\, and Novartis\nValidating novel Immunoassays\, bioanalytical and biodistribution technology with Astellas Gene Therapies and Boehringer Ingelheim\nUnderstanding possible risks around exacerbation of both the innate and adaptive immune response with Roche and Tenaya Therapeutics\nExploring the practicalities of AAV redosing through an immunology lens with the University of Indiana and Adolore Biotherapeutics\nExamine the immunogenicity risks specific to gene editing approached as momentum in the field increases with CRISPR and Modalis Therapeutics
URL:http://www.pharmajournalist.com/event/5th-gene-therapy-immunogenicity-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260515T172757
CREATED:20240523T112419Z
LAST-MODIFIED:20240529T133152Z
UID:39154-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:2nd ADC Linker & Conjugation Summit
DESCRIPTION:With Eli Lilly’s acquisition of Mablink and Novartis’ investment in Tagworks\, both centering on their innovative linker and conjugation technologies – optimizing linker chemistry and diversifying conjugation technologies to increase stability and selectivity are becoming increasingly more attractive to ADC developers as they strive for a competitive edge over their peers. \n \nAs part of the World ADC Series\, the 2nd ADC Linker & Conjugation Summit is the only forum exclusively focused on enhancing your linker and conjugation chemistry. With 100+ attendees ranging from boots-on-the-ground scientists working on improving linker & conjugation chemistries daily\, through to more senior directors\, this conference is the optimal combination of knowledge sharing and networking. \nLeave this summit with the confidence to innovate hydrophilic linkers that help prevent aggregation\, enhance stability in linkers & conjugations to ensure tumor targeting and hone site-specific conjugations to guarantee homogenous DAR\, all to ultimately ensure ADC stability and widen therapeutic index.
URL:http://www.pharmajournalist.com/event/2nd-adc-linker-conjugation-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240827
DTEND;VALUE=DATE:20240830
DTSTAMP:20260515T172757
CREATED:20240515T095016Z
LAST-MODIFIED:20240515T095016Z
UID:39106-1724716800-1724975999@www.pharmajournalist.com
SUMMARY:3rd Digital Biomarkers & Clinical Measures for Neurology Summit
DESCRIPTION:Delivering on the Promise of Precision Medicine with Digital Measures in Neurology \nHarnessing More Quantitative\, Objective & Less Invasive Measures to Reduce Costs & Improve Neurology Patient Experience \n2023 welcomed SV95C as the first ever digital endpoint qualified by a regulatory agency\, which means that the floodgates have now opened to the potential of digital biomarkers to transform clinical development in neurology. \nFrom the latest validated research on implementing speech\, cognition\, and motor tracking measures into clinical development\, to navigating the regulatory and commercial landscape\, the 3rd Digital Biomarkers & Clinical Measures for Neurology Summit is the ultimate platform to take your digital strategy to the next level. \nThis August\, join 80+ senior industry leaders across digital health\, medical affairs\, clinical development\, and regulatory this year from Biogen\, DEEP Measures\, Janssen\, Alexion Pharmaceuticals\, Eisai\, Pfizer\, Novo Nordisk\, Novartis\, Boehringer Ingelheim\, Takeda\, MTP\, BMS\, Alto Neurosciences\, Michael J. Fox Foundation\, Cerevel Therapeutics\, Regeneron and many more…
URL:http://www.pharmajournalist.com/event/3rd-digital-biomarkers-clinical-measures-for-neurology-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240827
DTEND;VALUE=DATE:20240830
DTSTAMP:20260515T172757
CREATED:20240730T144029Z
LAST-MODIFIED:20240730T144412Z
UID:39475-1724716800-1724975999@www.pharmajournalist.com
SUMMARY:3rd Oligonucleotide CMC & Analytical Development Summit
DESCRIPTION:Exclusively dedicated to uniting AD\, QC\, and CMC leaders the 3rd Oligonucleotide CMC & Analytical Development Summit is the only industry-led meeting solving your impurity\, regulatory\, and cost-efficiency challenges in this rapidly evolving field. \nAcross the three days\, you’ll get the chance to hear from KOLs like Ionis Pharmaceuticals\, AstraZeneca\, and CAMP4 Therapeutics as the present their data-driven case studies on managing quality\, regulatory affairs\, and cost-efficient manufacturing. \nDeep dive into the major challenges of streamlining analytical tools\, process development\, and look towards greener chemistries to ensure global uptake of oligonucleotide drugs. \nThis isn’t just an event\, it’s an investment in the future of your teams’ technical capabilities. Bringing together siRNA\, mRNA\, ASO\, oligo and oligo-conjugate developers\, this definitive summit fosters comprehensive development\, ensuring the resilience and longevity of this rapidly advancing modality. \nJoin us this August to assess the field\, take back actionable insights to your team\, and realize the potential of oligonucleotide therapeutics for prevalent diseases and improved market acceptance. \nEvent highlights: \n\n3 interactive workshops across CMC consideration\, oligo-conjugate analytical and detection methods\, and how to establish a robust control strategy\n18 data-driven case studies from complex oligo synthesis to scale-up and quality control. This is your end-to-end guide for oligo commercialization\n100+ industry experts across Analytical Development\, CMC and QC teams in attendance\, allowing you to connect\, benchmark and strive towards common goals together\n\nExpert speakers include: \n\nAngela Tsai\, Senior Manager – Collaboration & External Innovation\, Sanofi\nGeorge Bou-Assaf\, Associate Director\, Biogen\nHuijun Tian\, Director\, Analytical Development & Quality Control\, QurAlis\nIsaiah Cedillo\, Assistant Director – Manufacturing & Operations\, Ionis Pharmaceuticals\nJanine Tom\, Senior Principal Scientist\, Amgen\nSatya Kuchimanchi\, Senior Vice President\, Technical Operations\, Chemistry\, Manufacturing & Controls\, CAMP4 Therapeutics\n\n100+ Industry Experts | 3 Interactive Workshops | 20% Off Group Discounts | Data-Driven Case Studies \nTo know more visit: https://ter.li/eptndw
URL:http://www.pharmajournalist.com/event/3rd-oligonucleotide-cmc-analytical-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR